Abstract
The authors recently noted that due to a formatting error, several references in the Materials and Methods section had been inadvertently omitted from the reference list. The reference format is herewith corrected, and the references now display correctly in the reference list. The authors apologize for their oversight and any confusion it may have caused.
The references have been updated in the following sentences in the Materials and Methods section:
From, “The plasmid constructs (provided by Susan R. Weiss, University of Pennsylvania) described in (13) were: pLenti‐sgO1‐9 (targeting the OAS1 gene), pLenti‐sgO2‐5 (targeting the OAS2 gene in hTERT‐HME1 cells) and pLenti‐sgO2‐9 (targeting the OAS2 gene in PC3 cells), and pLenti‐sgO3‐9 (targeting the OAS3 gene).”
to, “The plasmid constructs (provided by Susan R. Weiss, University of Pennsylvania) described in (Li et al, 2016)…”
From, “To increase the expression of OAS1, OAS2, and OAS3 using pseudo lentivirus, we subcloned the cDNAs of human OAS1, OAS2, and OAS3, from our previous constructs (13), into pLenti‐CMV‐puro and pLenti‐CMV‐hygro using Gateway recombination cloning technology.”
to, “… from our previous constructs (Li et al, 2016), into pLenti‐CMV‐puro and pLenti‐CMV‐hygro using Gateway recombination cloning technology.”
From, “C t values were converted into relative gene expression levels compared to that of an internal control gene, GAPDH, using the ΔΔC t method (67).”
to, “… using the ΔΔC t method (Livak & Schmittgen, 2001).”
From, “Anti‐2‐5A was prepared with modifications of methods reported earlier (68).”
to, “Anti‐2‐5A was prepared with modifications of methods reported earlier (Knight et al, 1980).”
From, “5′‐triphosphoryl, 2′,5′‐tetraadenylate [(2′‐5′)p3A4] was enzymatically synthesized and purified by HPLC as described earlier (69) and the conjugation of 2‐5A with biotin was as described in (70). The (2′‐5′)p3A4‐biotin was tested for functional activity in a FRET based RNase L activation assay and used for competitive ELISA assay on a Streptavidin coated plates (Thermo Scientific) as described below (71).”
to, “5′‐triphosphoryl, 2′,5′‐tetraadenylate [(2′‐5′)p3A4] was enzymatically synthesized and purified by HPLC as described earlier (Jha et al, 2011) and the conjugation of 2‐5A with biotin was as described in (Thakur et al, 2007). The (2′‐5′)p3A4‐biotin was tested for functional activity in a FRET based RNase L activation assay and used for competitive ELISA assay on a Streptavidin coated plates (Thermo Scientific) as described below (Townsend et al, 2008).”
From, “In vitro synthesis of PAR modified with AMP (PAR‐2‐5A) was performed enzymatically utilizing purified recombinant hexa‐histidine tagged human OAS1 p42 (49).”
to, “… utilizing purified recombinant hexa‐histidine tagged human OAS1 p42 (Molinaro et al, 2006).”
Correction to: The EMBO Journal (2020) 39: e101573. DOI 10.15252/embj.2019101573 | Published online 23 April 2020
References
- Jha BK, Polyakova I, Kessler P, Dong B, Dickerman B, Sen GC, Silverman RH (2011) Inhibition of RNase L and RNA‐dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity. J Biol Chem 286: 26319–26326 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Knight M, Cayley PJ, Silverman RH, Wreschner DH, Gilbert CS, Brown RE, Kerr IM (1980) Radioimmune, radiobinding and HPLC analysis of 2‐5A and related oligonucleotides from intact cells. Nature 288: 189–192 [DOI] [PubMed] [Google Scholar]
- Li Y, Banerjee S, Wang Y, Goldstein SA, Dong B, Gaughan C, Silverman RH, Weiss SR (2016) Activation of RNase L is dependent on OAS3 expression during infection with diverse human viruses. Proc Natl Acad Sci USA 113: 2241–2246 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real‐time quantitative PCR and the 2(‐Delta Delta C(T)) Method. Methods 25: 402–408 [DOI] [PubMed] [Google Scholar]
- Molinaro RJ, Jha BK, Malathi K, Varambally S, Chinnaiyan AM, Silverman RH (2006) Selection and cloning of poly(rC)‐binding protein 2 and Raf kinase inhibitor protein RNA activators of 2′,5′‐oligoadenylate synthetase from prostate cancer cells. Nucleic Acids Res 34: 6684–6695 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thakur CS, Jha BK, Dong B, Das Gupta J, Silverman KM, Mao H, Sawai H, Nakamura AO, Banerjee AK, Gudkov A et al (2007) Small‐molecule activators of RNase L with broad‐spectrum antiviral activity. Proc Natl Acad Sci USA 104: 9585–9590 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Townsend HL, Jha BK, Han JQ, Maluf NK, Silverman RH, Barton DJ (2008) A viral RNA competitively inhibits the antiviral endoribonuclease domain of RNase L. RNA 14: 1026–1036 [DOI] [PMC free article] [PubMed] [Google Scholar]